Ozempic’s Success Is Bad News for Rivals

Watch Bloomberg Businessweek Daily LIVE every day on YouTube: http://bit.ly/3vTiACF.President Donald Trump said he was prepared for a legal fight with Federal Reserve Governor Lisa Cook after he moved to oust her from her post following allegations that she falsified mortgage doc ... Show More

Sales of new US homes exceeded forecasts in July after an upward revision to the prior month, as prices eased and heavy incentives enticed more buyers off the fence. Contract signings on new single-family homes ticked down to a 652,000 annualized rate, with the strongest demand i ... Show More

President Donald Trump moved to oust Federal Reserve Governor Lisa Cook from her post at the US central bank in the wake of allegations from a White House ally that she falsified documents on mortgage applications. “The American people must be able to have full confidence in the ... Show More

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More

Bloomberg BNA's Eleanor Tyler joins Tom Keene and Mike McKee to discuss pharmaceutical mergeres, tax inversions, drug pricing, and the renewed efforts by the Federal Trade Commission to regulate an increasingly complicated industry. Learn more about your ad-choices at https://www ... Show More

Moderna CEO Stephane Bancel talks about the Moderna vaccine, drug prices, and future of the company with Bloomberg's Paul Sweeny and Matt Miller. See omnystudio.com/listener for privacy information. 

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ... Show More

As a number of existing therapies are being re-purposed to help patients with the most severe Covid-19 symptoms, we speak to a UK-based bioscience company about a drug they've developed and explore how it is being used in Italy.  Guests: Tom Whipple, The Times science editorSomei ... Show More

In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 10,000 time ... Show More

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More